Study #2020-1084
PET Imaging of Hepatocellular Carcinoma with 18F-FSPG
MD Anderson Study Status
Enrolling
Treatment Agent
Fluorine F 18 L-glutamate Derivative 18F-FSPG, Carbon C 11 Acetate, Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Description
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma, Benign Liver Tumor, Metastases to Liver
Study phase:
Phase I
Physician name:
Simone Krebs
Department:
Nuclear Medicine
For general questions about clinical trials:
1-866-254-1401
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.